CAS NO: | 69739-16-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Cefodizime is a third generation cephalosporinantibioticwith a broad spectrum of antibacterial activity. Cefodizime has no renal toxic effect, good tolerance and immune regulation activity, and has the potential for severe infections of the respiratory and urinary tracts[1][2]. | ||||||||||||||||
IC50& Target | Bacterial[1] | ||||||||||||||||
体外研究 (In Vitro) | Enterobacteriaceae includingEscherichia coli,Klebsiella pneumoniae,Morganella morgan ii,Proteus mirabilis,Proteus vulgaris,Shigella sonnei,Yersinia enterocoliticaandSalmonellaspecies are all consistently sensitive to Cefodizime in vitro. Cefodizime has marginal but variable inhibitory activity againstCitrobacterspecies includingCitrobacter freundii, andSerratia marcescens. Cefodizime inhibits other Gram-negative bacteria includingHaemophilus irifluenzae,Moraxella catarrhalis,Neisseria gonorrhoeaeandNeisseria meningitidis[1]. | ||||||||||||||||
体内研究 (In Vivo) | In experimentally-inducedK. pneumoniaerespiratory tract infections in mice, Cefodizime has activity comparable to Cefotaxime and Ceftazidime, and greater than that of Cefoperazone, Latamoxef, Cefuroxime or cefazolin for 8 hours after a single subcutaneous dose of 50 mg/kg. However, unlike these cephalosporins, Cefodizime continues to demonstrate pronounced bactericidal activity for at least 48 hours after a single injection. Complete bacterial clearance from the lung is achieved within 48 hours in 50% of the mice although Cefodizime is no longer detectable in the serum[1]. | ||||||||||||||||
分子量 | 584.67 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C20H20N6O7S4 | ||||||||||||||||
CAS 号 | 69739-16-8 | ||||||||||||||||
中文名称 | 头孢地嗪 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 20.83 mg/mL(35.63 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|